Medications for Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease)

These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease).

Found 3 Approved Drugs for Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease)

Riluzole

Brand Names
Tiglutik, Teglutik

Riluzole

Brand Names
Tiglutik, Teglutik
Form: Tablet, Liquid
Method of administration: Oral
FDA approval date: June 18, 2013
Classification: Benzothiazole
Riluzole is indicated for the treatment of amyotrophic lateral sclerosis (ALS). Riluzole is indicated for the treatment of amyotrophic lateral sclerosis (ALS) ( 1 )

Radicava

Generic Name
Edaravone

Radicava

Generic Name
Edaravone
Form: Injection, Kit, Solution
Method of administration: Intravenous
FDA approval date: May 05, 2017
Edaravone injection is indicated for the treatment of amyotrophic lateral sclerosis (ALS). Edaravone injection is indicated for the treatment of amyotrophic lateral sclerosis (ALS). ( 1 )

Qalsody

Generic Name
Tofersen

Qalsody

Generic Name
Tofersen
Form: Injection
Method of administration: Intrathecal
FDA approval date: April 25, 2023
Classification: Antisense Oligonucleotide
QALSODY is indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 ( SOD1 ) gene. This indication is approved under accelerated approval based on reduction in plasma neurofilament light chain (NfL) observed in patients treated with QALSODY. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trial(s). QALSODY is an antisense oligonucleotide indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 ( SOD1 ) gene. This indication is approved under accelerated approval based on reduction in plasma neurofilament light chain observed in patients treated with QALSODY. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trial(s). ( 1 )
Showing 1-3 of 3
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances